Skip to main content

Boston Scientific income statement

  • BSX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$44.34+0.32%Close 13 Nov 2026 · Market value $63.59B

Boston Scientific reported revenue of $20.1 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 19.9% from fiscal 2024. Net income was $2.90 billion and diluted earnings per share $1.94.

From Boston Scientific's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Boston Scientific income statement, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$8.36B$8.05B$8.19B$7.81B$7.62B$7.25B$7.14B$7.46B$8.07B$9.08B$9.05B$9.82B$10.73B$9.91B$11.89B$12.68B$14.24B$16.75B$20.07B$21.07B
Revenue growth—−3.7%+1.7%−4.7%−2.4%−4.9%−1.5%+4.5%+8.1%+12.5%−0.3%+8.6%+9.3%−7.7%+19.9%+6.7%+12.3%+17.6%+19.9%—
Cost of revenue$2.34B$2.47B$2.58B$2.60B$2.66B$2.35B$2.17B$2.21B$2.17B$2.42B$2.59B$2.81B$3.12B$3.46B$3.71B$3.96B$4.34B$5.26B$6.22B$6.50B
Gross profit$6.01B$5.58B$5.61B$5.21B$4.96B$4.90B$4.97B$5.17B$5.30B$5.96B$6.46B$7.01B$7.62B$6.45B$8.18B$8.73B$9.90B$11.49B$13.85B$14.57B
Gross margin72.0%69.3%68.5%66.7%65.1%67.6%69.6%69.3%65.7%65.7%71.3%71.4%71.0%65.0%68.8%68.8%69.5%68.6%69.0%69.1%
Selling, general and administrative$2.91B$2.59B$2.63B$2.58B$2.49B$2.54B$2.67B$2.90B$2.87B$3.10B$3.29B$3.57B$3.94B$3.79B$4.36B$4.52B$5.19B$5.98B$6.89B$7.10B
Operating expenses$6.03B$7.09B$6.51B$5.86B$4.06B$8.77B$4.85B$5.47B$5.59B$5.51B$5.17B$5.50B$6.10B$6.53B$6.98B$7.08B$7.55B$8.89B$10.24B$10.64B
Operating income−$14.00M−$1.50B−$894.0M−$656.0M$904.0M−$3.87B$120.0M−$301.0M−$283.0M$447.0M$1.28B$1.51B$1.52B−$80.00M$1.20B$1.65B$2.34B$2.60B$3.61B$3.93B
Operating margin−0.2%−18.7%−10.9%−8.4%11.9%−53.4%1.7%−4.0%−3.5%4.9%14.2%15.3%14.1%−0.8%10.1%13.0%16.5%15.5%18.0%18.7%
Interest expense$570.0M$468.0M$407.0M$393.0M$281.0M$261.0M$324.0M$216.0M$284.0M$233.0M$229.0M$241.0M$473.0M$361.0M$341.0M$470.0M$265.0M$305.0M$349.0M$376.0M
Other income and expense—−$526.0M−$414.0M−$407.0M−$262.0M−$239.0M−$343.0M−$208.0M−$367.0M−$270.0M−$353.0M−$85.00M−$831.0M$1.00M−$123.0M−$508.0M−$358.0M———
Income before tax−$569.0M−$2.03B−$1.31B−$1.06B$642.0M−$4.11B−$223.0M−$509.0M−$650.0M$177.0M$933.0M$1.42B$687.0M−$79.00M$1.08B$1.14B$1.99B$2.28B$3.38B$3.65B
Income tax expense−$74.00M$5.00M−$283.0M$2.00M$201.0M−$39.00M−$102.0M−$390.0M−$411.0M−$170.0M$828.0M−$249.0M−$4.01B$2.00M$36.00M$443.0M$393.0M$436.0M$493.0M$162.0M
Effective tax rate13.0%−0.2%21.6%−0.2%31.3%0.9%45.7%76.6%63.2%−96.0%88.7%−17.5%−584%−2.5%3.3%38.8%19.8%19.1%14.6%4.4%
Net income−$495.0M−$2.04B−$1.02B−$1.06B$441.0M−$4.07B−$121.0M−$119.0M−$239.0M$347.0M$104.0M$1.67B$4.70B−$115.0M$985.0M$642.0M$1.57B$1.85B$2.90B$3.50B
Net margin−5.9%−25.3%−12.5%−13.6%5.8%−56.1%−1.7%−1.6%−3.0%3.8%1.1%17.0%43.8%−1.2%8.3%5.1%11.0%11.1%14.4%16.6%
Net income to common shareholders———————————$1.67B$4.70B−$115.0M$985.0M$642.0M$1.57B$1.85B$2.90B$3.50B
EPS · diluted−$0.33−$1.36−$0.68−$0.70$0.29−$2.89−$0.09−$0.09−$0.18$0.25$0.08$1.19$3.33−$0.08$0.69$0.45$1.07$1.25$1.94$2.37
Diluted weighted average shares1.5B1.5B1.5B1.5B1.5B1.4B1.3B1.3B1.3B1.4B1.4B1.4B1.4B1.4B1.4B1.4B1.5B1.5B1.5B1.5B
Basic weighted average shares1.5B1.5B1.5B1.5B1.5B1.4B1.3B1.3B1.3B1.4B1.4B1.4B1.4B1.4B1.4B1.4B1.5B1.5B1.5B1.5B
EBITDA$904.0M−$641.0M−$60.00M$160.0M$1.62B−$3.19B$809.0M$424.0M$486.0M$1.26B$2.13B$2.40B$2.53B$1.04B$2.29B$2.79B$3.54B$3.87B$4.98B$5.36B
EBITDA margin10.8%−8.0%−0.7%2.0%21.3%−43.9%11.3%5.7%6.0%13.9%23.5%24.4%23.6%10.5%19.3%22.0%24.9%23.1%24.8%25.5%
Depreciation & amortization$918.0M$864.0M$834.0M$816.0M$717.0M$683.0M$689.0M$725.0M$769.0M$815.0M$844.0M$894.0M$1.01B$1.12B$1.09B$1.14B$1.20B$1.27B$1.37B$1.43B
Stock-based compensation$122.0M$138.0M$144.0M$150.0M$128.0M$108.0M$105.0M$103.0M$107.0M$116.0M$127.0M$140.0M$157.0M$170.0M$194.0M$220.0M$233.0M$266.0M$299.0M$313.0M

Quarterly

Boston Scientific income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$3.73B$3.86B$4.12B$4.21B$4.56B$4.66B$5.06B$5.07B$5.29B$5.20B$5.44B$5.14B
Cost of revenue$1.15B$1.21B$1.27B$1.31B$1.47B$1.45B$1.64B$1.52B$1.61B$1.59B$1.59B$1.71B
Gross profit$2.58B$2.65B$2.85B$2.90B$3.10B$3.21B$3.42B$3.54B$3.68B$3.61B$3.85B$3.43B
Gross margin69.2%68.7%69.2%68.8%67.9%68.8%67.7%69.9%69.6%69.5%70.7%66.7%
Selling, general and administrative$1.38B$1.36B$1.45B$1.56B$1.61B$1.60B$1.72B$1.74B$1.83B$1.78B$1.80B$1.68B
Operating expenses$2.00B$1.97B$2.33B$2.16B$2.42B$2.29B$2.60B$2.49B$2.85B$2.51B$2.67B$2.60B
Operating income$584.0M$675.0M$520.0M$733.0M$675.0M$921.0M$819.0M$1.05B$825.0M$1.10B$1.18B$828.0M
Operating margin15.7%17.5%12.6%17.4%14.8%19.8%16.2%20.7%15.6%21.2%21.6%16.1%
Interest expense$65.00M$69.00M$77.00M$79.00M$80.00M$82.00M$90.00M$87.00M$90.00M$90.00M$96.00M$100.0M
Other income and expense−$79.00M−$67.00M−$100.0M−$65.00M————————
Income before tax$505.0M$608.0M$420.0M$669.0M$585.0M$805.0M$941.0M$939.0M$700.0M$1.16B$1.06B$733.0M
Income tax expense$1.00M$115.0M$98.00M$200.0M$23.00M$133.0M$146.0M$183.0M$30.00M−$176.0M$155.0M$153.0M
Effective tax rate0.2%18.9%23.3%29.9%3.9%16.5%15.5%19.5%4.3%−15.1%14.6%20.9%
Net income$505.0M$495.0M$324.0M$469.0M$565.0M$674.0M$797.0M$755.0M$672.0M$1.34B$907.0M$582.0M
Net margin13.6%12.8%7.9%11.1%12.4%14.5%15.7%14.9%12.7%25.8%16.7%11.3%
Net income to common shareholders$505.0M$495.0M$324.0M$469.0M$565.0M$674.0M$797.0M$755.0M$672.0M$1.34B$907.0M$582.0M
EPS · diluted$0.34$0.33$0.22$0.32$0.38$0.45$0.53$0.51$0.45$0.90$0.61$0.40
Diluted weighted average shares1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.5B
Basic weighted average shares1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.5B1.4B
EBITDA$897.0M$979.0M$831.0M$1.04B$1.02B$1.25B$1.16B$1.39B$1.19B$1.45B$1.53B$1.19B
EBITDA margin24.1%25.4%20.2%24.7%22.4%26.7%22.8%27.4%22.5%27.9%28.2%23.1%
Depreciation & amortization$313.0M$304.0M$311.0M$307.0M$348.0M$325.0M$336.0M$342.0M$365.0M$351.0M$355.0M$361.0M
Stock-based compensation$59.00M$63.00M$66.00M$68.00M$69.00M$74.00M$75.00M$79.00M$71.00M$83.00M$87.00M$72.00M

The main figures as JSON and plain text. See data and methodology.

BSX in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.